Jane Sarginson1, Roger T Webb2, S Jill Stocks3, Aneez Esmail3, Shruti Garg4, Darren M Ashcroft5. 1. NIHR Greater Manchester Primary Care Patient Safety Translational Research Centre, University of Manchester; Centre for Pharmacoepidemiology and Drug Safety, Manchester Academic Health Sciences Centre (MAHSC). Electronic address: jane.sarginson@manchester.ac.uk. 2. Division of Psychology & Mental Health, University of Manchester. 3. NIHR Greater Manchester Primary Care Patient Safety Translational Research Centre, University of Manchester. 4. Division of Neuroscience and Experimental Psychology, University of Manchester. 5. NIHR Greater Manchester Primary Care Patient Safety Translational Research Centre, University of Manchester; Centre for Pharmacoepidemiology and Drug Safety, Manchester Academic Health Sciences Centre (MAHSC).
Abstract
BACKGROUND: The prevalence of antidepressant prescribing in children and adolescents increased steadily in the United States and parts of Europe between 2005 and 2012 despite regulatory safety warnings. Little is known about the characteristics of those being prescribed antidepressants for the first time. METHODS: A longitudinal study of antidepressant prescribing in 3-17 year olds was carried out using data from the UK Clinical Practice Research Datalink (CPRD) between 2000 and 2015. Changes in the incidence of first ever antidepressant prescriptions and the characteristics of those being prescribed them was examined. RESULTS: Incidence of first ever prescriptions nearly doubled between 2006 and 2015 rising from 1.60 (95%CI: 1.51, 1.69) to 3.12 (3.00, 3.25) per 1000 person years. Only 21% of the 1721 patients with incident prescriptions in 2015 could be linked to a depression diagnosis, with an additional 22% of prescriptions linked to alternative indications. The incidence of prescriptions linked to a depression diagnosis increased between 2012 and 2015, with an adjusted incidence rate ratio of 1.46 (1.26, 1.70). Antidepressant prescribing for depression and other indications has been increasing most rapidly in 15 to 17 year old females. LIMITATIONS: Diagnoses are not directly linked to prescriptions in CPRD, so linkage must be inferred by temporal proximity. CONCLUSIONS: Antidepressant prescribing in children increased between 2006 and 2015. This is, at least in part, due to a rise in alternative uses of antidepressants, including the treatment of anxiety, chronic pain and migraines.
BACKGROUND: The prevalence of antidepressant prescribing in children and adolescents increased steadily in the United States and parts of Europe between 2005 and 2012 despite regulatory safety warnings. Little is known about the characteristics of those being prescribed antidepressants for the first time. METHODS: A longitudinal study of antidepressant prescribing in 3-17 year olds was carried out using data from the UK Clinical Practice Research Datalink (CPRD) between 2000 and 2015. Changes in the incidence of first ever antidepressant prescriptions and the characteristics of those being prescribed them was examined. RESULTS: Incidence of first ever prescriptions nearly doubled between 2006 and 2015 rising from 1.60 (95%CI: 1.51, 1.69) to 3.12 (3.00, 3.25) per 1000 person years. Only 21% of the 1721 patients with incident prescriptions in 2015 could be linked to a depression diagnosis, with an additional 22% of prescriptions linked to alternative indications. The incidence of prescriptions linked to a depression diagnosis increased between 2012 and 2015, with an adjusted incidence rate ratio of 1.46 (1.26, 1.70). Antidepressant prescribing for depression and other indications has been increasing most rapidly in 15 to 17 year old females. LIMITATIONS: Diagnoses are not directly linked to prescriptions in CPRD, so linkage must be inferred by temporal proximity. CONCLUSIONS: Antidepressant prescribing in children increased between 2006 and 2015. This is, at least in part, due to a rise in alternative uses of antidepressants, including the treatment of anxiety, chronic pain and migraines.
Authors: Karlijn J Joling; Harm W J van Marwijk; Ellen Piek; Henriëtte E van der Horst; Brenda W Penninx; Peter Verhaak; Hein P J van Hout Journal: J Affect Disord Date: 2011-05-24 Impact factor: 4.839
Authors: John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe Journal: JAMA Date: 2004-08-18 Impact factor: 56.272
Authors: Tim Doran; Evangelos Kontopantelis; Jose M Valderas; Stephen Campbell; Martin Roland; Chris Salisbury; David Reeves Journal: BMJ Date: 2011-06-28
Authors: Marilyn N Vera-Chang; Antony D St-Jacques; Rémi Gagné; Chris J Martyniuk; Carole L Yauk; Thomas W Moon; Vance L Trudeau Journal: Proc Natl Acad Sci U S A Date: 2018-12-10 Impact factor: 11.205
Authors: Michael Fleming; Catherine A Fitton; Markus F C Steiner; James S McLay; David Clark; Albert King; Daniel F Mackay; Jill P Pell Journal: Int J Epidemiol Date: 2020-08-01 Impact factor: 7.196
Authors: Catharine Morgan; Roger T Webb; Matthew J Carr; Evangelos Kontopantelis; Jonathan Green; Carolyn A Chew-Graham; Nav Kapur; Darren M Ashcroft Journal: BMJ Date: 2017-10-18
Authors: Ruth H Jack; Chris Hollis; Carol Coupland; Richard Morriss; Roger David Knaggs; Andrea Cipriani; Samuele Cortese; Julia Hippisley-Cox Journal: Evid Based Ment Health Date: 2019-06-28
Authors: Paul A Tiffin; Jose L Mediavilla; Helen Close; Adetayo S Kasim; Patrick Welsh; Lewis W Paton; James M Mason Journal: BMJ Open Date: 2019-08-07 Impact factor: 2.692
Authors: Marilyn N Vera-Chang; Antony D St-Jacques; Chunyu Lu; Thomas W Moon; Vance L Trudeau Journal: Front Neurosci Date: 2019-09-19 Impact factor: 4.677